Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics, page-10

The efficacy of PI3K-AKT-mTOR in breast cancer would alter the potential market for Pax from 3.19 per 100,000 to 132.49 per 100,000 - an increase in market size of 4,153 percent. When investor perception of Kazia transitions from the company being a brain cancer stock to being a breast cancer stock, there will be a dramatic readjustment in valuation. Given that PI3K-AKT-mTOR is also being applied to the even larger market of heart disease, the potential price appreciation for Kazia is almost unimaginable and makes this seemingly interminable wait worthwhile. The company is at the cutting edge of medical science, exactly the right place at exactly the right time. Now it is a matter of executing.